Leucine-rich-repeat-containing G protein-coupled receptors (LGRs) have been widely found to be implicated with development and progression in multiple cancer types. However, the clinical significance and biological functions of LGR6 in ovarian cancer remains unclear. In this study, LGR6 expression was mainly examined by immunohistochemistry. Functional assays in vitro and animal experiments in vivo were carried out to explore the effect of LGR6 on cancer stem cell (CSC) characteristics and chemotherapeutic responses in ovarian cancer cells. Luciferase assays and GSEA were used to discern the underlying mechanisms contributing to the roles of LGR6 in ovarian cancer. Here, we reported that LGR6 was upregulated in ovarian cancer, which positively correlated with poor chemotherapeutic response and progression survival in ovarian cancer patients. Loss-of-function assays showed that downregulating LGR6 abrogated the CSC-like phenotype and chemoresistance in vitro. More importantly, silencing LGR6 improved the chemoresistance of ovarian cancer cells to cisplatin in vivo. Mechanistic investigation further revealed that silencing LGR6 inhibited stemness and chemoresistance by repressing Wnt/b-catenin signaling. Collectively, our results uncover a novel mechanism contributing to LGR6-induced chemotherapeutic resistance in ovarian cancer, providing the evidence for LGR6 as a potential therapeutic target in ovarian cancer.
INTRODUCTION
Ovarian cancer is one of the most common gynecological malignancies, as well as one of the leading causes responsible for the cancer-related deaths in females. 1 Despite substantial improvements in treatment of ovarian cancer in the past several decades, the prognosis of ovarian cancer patients is still dismal, which is largely attributed to chemotherapeutic resistance after a long period of treatment. Cancer stem cells (CSCs) that are a minority population of cells with the abilities of unrestrained proliferation and selfrenewal have been identified to contribute to the failure of chemotherapy in ovarian cancer patients. 2, 3 Several lines of evidence have reported that CSCs are crucial mediators in the induction and maintenance of chemotherapeutic resistance in several human cancers, 4, 5 including ovarian cancer. 6, 7 Thus, identification of the underlying mechanisms that induce and maintain CSC properties will heighten the efficacy of chemotherapeutics and improve prognosis in ovarian cancer patients.
Wnt/b-catenin signaling pathways are a group of signal transduction pathways consisting of several ligands and receptor proteins that passed transduction signal from outside the cell to the inside. The ligands binding to receptors trigger signaling pathways that play a crucial role in embryonic development and tissue regeneration. 8, 9 The constitutive activation of Wnt/b-catenin signaling has been extensively identified to be implicated in multifaceted aspects of cancers, including cancer dormancy, metastasis, and progression. 10, 11 Furthermore, mounting studies have reported that sustained activation of canonical Wnt/b-catenin signaling is pivotal in inducing and maintaining CSC features in various types of cancer. [12] [13] [14] Likewise, Wnt/b-catenin signaling has been reported to be required for CSCs in ovarian cancer. Chen et al. 15 has found that STAT3 was found to be hyperactivated in ovarian cancer spheroids, where activity of Wnt/b-catenin was indispensable for STAT3-induced or maintained stemness in ovarian cancer cells; moreover, Mariya and colleagues 16 have reported that MMP10 promoted stemness and chemotherapeutic resistance of ovarian cancer stem-like cells by activating Wnt/b-catenin signaling. Therefore, further elucidating the mechanisms responsible for constitutive activation of Wnt signaling in ovarian cancer is of paramount importance.
Leucine-rich-repeat-containing G protein-coupled receptor (LGR) is a subgroup of the seven-transmembrane G protein-coupled superfamily and is well-known for the member proteins LGR4-6. 17 Much research efforts have been recently made to explore the biological functions of LGR4-6 in multiple human cancer types. [18] [19] [20] [21] Interestingly, numerous studies have reported that LGR4-6 play crucial roles in activation of Wnt/b-catenin signaling via binding to R-spondins (Rspo1-4). [22] [23] [24] However, the clinical significances and biological roles of LGR4-6 in ovarian cancers, as well as the regulatory functions of LGR4-6 on Wnt/b-catenin signaling in the context of ovarian cancers, have yet not to be elucidated. Here, our results reported that LGR6, not LGR4 or LGR5, was dramatically upregulated in ovarian cancer tissues, and overexpression of LGR6 significantly correlated with poor clinicopathological characteristics, as well as predicted poor overall and progression-free survival in ovarian cancer patients. Loss-of-function assays showed that silencing LGR6 repressed the stemness and improved chemoresistance of ovarian cancer cells. Mechanistic investigation further revealed that LGR6 promoted stemness and chemoresistance via Wnt/b-catenin signaling in ovarian cancer cells. Thus, our results indicate that LGR6 might be used as a potential therapeutic target in ovarian cancer. LGR4-6 expression in six ovarian cancer tissues and four normal ovarian epithelial tissues by western blotting. (C and D) Western blotting (C) and real-time PCR (D) of LGR6 expression in one normal ovarian epithelial cell HOSEpiC and eight ovarian cancer cell lines. GAPDH was used as an endogenous control in RT-PCR, and a-tubulin was detected as a loading control in the western blot. Error bars represent the mean ± SD of three independent experiments. *p < 0.05.
RESULTS

LGR6 Is Upregulated in Ovarian Cancer
To determine the expression levels of different members of the LGR family in ovarian cancer, six ovarian cancer tissues and four normal ovarian tissues were collected, and LGR4, LGR5, and LGR6 were further examined in these tissues by realtime PCR and western blot. As shown in Figures 1A and 1B , mRNA and protein levels of LGR6 were dramatically upregulated, and LGR5 was slightly increased in ovarian cancer tissues compared with those in normal ovarian tissues, but there was no significant difference of LGR4 expression between in ovarian cancer tissues and normal ovarian tissues. We further examined the expression levels of LGR6 in one ovarian epithelial cell line, HOSEpiC, and eight ovarian cancer cells, respectively, and found that LGR6 expression was differentially enhanced in ovarian cancer cells compared with that in HOSEpiC ( Figures 1C and 1D ). These results demonstrated that high levels of LGR6 may be implicated in the pathogenesis of ovarian cancer.
Overexpression of LGR6 Predicts Poor Prognosis and Progression
We further determined the clinical significance of LGR6 in different histologic types of ovarian cancer by immunohistochemistry (IHC) (Tables S1 and S2). As shown in Figures 2A-2C, LGR6 expression levels were robustly and significantly upregulated in different histologic types of ovarian cancer, including serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, and clear-cell adenocarcinoma, compared with those in normal ovarian epithelial tissues, particularly in high-grade serous adenocarcinoma, and high expression of LGR6 was detected in 153/294 ovarian cancer tissues (52.0%). The correlation of LGR6 with clinicopathological features in ovarian cancer patients were further investigated, and the results showed that high expression of LGR6 positively correlated with histologic types, International Federation of Gynecology and Obstetrics (FIGO) stages, poor chemotherapeutic response, and poor progression in ovarian cancer patients (Figures 2D and 2E ; Table S3 ). Kaplan-Meier survival analysis indicated that overexpression of LGR6 was significantly associated with poor progression-free survivals in ovarian cancer patients ( Figure 2F ). The analysis result of www.moleculartherapy.org the ovarian cancer dataset from Kaplan-Meier plotter further revealed that high expression of LGR6 predicted poorer overall and progression-free survival in ovarian cancer patients ( Figures 2G and 2H) . Therefore, these results indicated that the high expression of LGR6 is closely associated with poor prognosis and disease progression in ovarian cancer patients.
Silencing LGR6 Represses Stemness in Ovarian Cancer
The above-mentioned findings indicated that high levels of LGR6 significantly contributed to poor progression in ovarian cancer patients. Accumulating evidence has shown that existence of CSCs promote the early progression and recurrence in a variety of cancers. 25 Figure 3C ). Spheroid formation assay was performed first, and the results showed that silencing LGR6 suppressed spheroid formation ability in ovarian cancer cells (Figure 3D ). Side population (SP) analysis showed that downregulating LGR6 reduced the fraction of SP cells ( Figure 3E ). The CD133 + population of ovarian cancer cells was repressed by silencing LGR6 via flow cytometry ( Figure 3F ). The effects of LGR6 on expression levels of stem-cell factors, including ABCG2, OCT4, SOX2, NANOG, and KLF4, were further examined via RT-PCR, and the results showed that silencing LGR6 reduced the expression of these factors ( Figure 3G ). These results demonstrated that silencing LGR6 repressed CSC characteristics in ovarian cancer cells.
Silencing LGR6 Attenuates Chemoresistance of Ovarian Cancer Cells
The previous results indicated that overexpression of LGR6 was positively correlated with poor chemotherapeutic response in ovarian cancer patients, to which CSCs have been reported to contribute. 6,7 Therefore, we further examined the effects of LGR6 on therapeutic response of ovarian cancer cells to different chemotherapies commonly used in ovarian cancer patients. Cell-viability assays showed that silencing LGR6 decreased the viability of ovarian cancer cells under treatment of cisplatin or paclitaxel ( Figure 4A ). Similarly, silencing LGR6 dramatically enhanced the apoptosis rate of ovarian cancer cells treated with cisplatin or paclitaxel (Figure 4B ). Mitochondrial membrane potential assay revealed that silencing LGR6 inhibited the mitochondrial potential of ovarian cancer cells after treatment of cisplatin or paclitaxel ( Figure 4C ). The effect of silencing LGR6 on the expression of anti-apoptotic proteins Bcl-2 and Bcl-xL and caspase-3 and -9 activity was further examined. As shown in Figures 4D-4F , silencing LGR6 elevated the activity of caspase-3 and -9 but reduced the expression of Bcl-2 and Bcl-xL in ovarian cancer cells. Collectively, these results indicate that silencing LGR6 abrogates chemoresistance in ovarian cancer cells.
Silencing LGR6 Improves Chemoresistance In Vivo
We further investigated the effects of LGR6 on the chemoresistance of ovarian cancer cells in vivo. Mice were randomly divided into two groups (n = 5/group). The SK-OV-3 vector or LGR6 sh#1 cells were inoculated subcutaneously into two groups in the left dorsal flank, respectively. Then, both groups of mice were intraperitoneally injected with cisplatin (2 mg/kg.day) every 5 days after 12 days of cells inoculation ( Figure 5A ). As shown in Figures 5A-5C, the tumor volumes and weight in the mice injected with the LGR6 sh#1 cells were dramatically reduced compared to those in the vector group. Furthermore, LGF6 expression levels were downregulated in the tumor tissues of the mice injected with the LGR6 sh#1 cells at the end of the experiment ( Figure 5D ); conversely, caspase-3 and -9 activity were remarkably elevated (Figures 5E and 5F). Thus, these findings indicated that silencing LGR6 re-sensitizes ovarian cancer cells to cisplatin in vivo.
Silencing LGR6 Inhibits Canonical Wnt Signaling
To uncover the mechanism underlying the effect of LGR6 on chemoresistance in ovarian cancer, gene set enrichment analysis (GSEA: http://software.broadinstitute.org/gsea/index.jsp) of LGR6 expression against the oncogenic signatures collection of the MSigDB (http://software.broadinstitute.org/gsea/msigdb/index.jsp) was performed. As shown in Figure 6A, LGR6 expression level was significant and positively correlated with the activity of canonical Wnt signaling. Western blot analysis revealed that silencing LGR6 reduced nuclear expression of b-catenin in ovarian cancer cells ( Figure 6B ). TOP/FLASH activity was downregulated in LGR6-silenced ovarian cancer cells compared with that in the vector cells ( Figure 6C ). The effect of LGR6 downregulation on downstream target genes of Wnt/b-catenin signaling was further investigated, and the results indicated that silencing LGR6 significantly reduced the expression of multiple downstream target genes of Wnt/b-catenin signaling ( Figure 6D ). These results indicated that inhibition of LGR6 inhibits activity of canonical Wnt/b-catenin signaling in ovarian cancer cells. In LGR6-silenced ovarian cancer cells, S33Y, which was used to constitutively activate Wnt/b-catenin signaling as a mutant-b-catenin (serine 33 to tyrosine), 27 was further transfected to investigate the functional role of Wnt/b-catenin signaling in the regulatory functions of LGR6 in stemness and chemoresistance in ovarian cancer cells. First, S33Y significantly reversed activity of Wnt/b-catenin signaling repressed by LGR6 downregulation in ovarian cancer cells (Figure 7A) . Spheroid formation assay and flow cytometry showed that S33Y significantly enhanced the stemness in LGR6-silenced cells (Figures 7B-7D) . Consistently, the chemoresistant ability of the LGR6-silenced ovarian cancer cells to cisplatin or paclitaxel were dramatically elevated by S33Y ( Figure 7E ). Therefore, these results indicated that silencing LGR6 inhibits stemness and chemoresistance of ovarian cancer cells via repressing canonical Wnt/b-catenin signaling.
DISCUSSION
The pivotal findings of this study provide insights into the functional role of LGR6 in ovarian cancer. In the present manuscript, our results demonstrated that LGR6 was upregulated in ovarian cancer tissues, which positively correlated with shorter overall and progressionfree survival in ovarian cancer patients. In addition, silencing LGR6 not only inhibited CSC-like phenotypes, but also attenuated the chemoresistance of ovarian cancer cells in vitro and in vivo. Our results further revealed that silencing LGR6-induced suppression of stemness and chemoresistance in ovarian cancer tissues was dependent on Wnt/b-catenin signaling. Therefore, our findings unravel a novel mechanism by which LGR6 promotes the CSC characteristics and chemoresistance in ovarian cancer cells.
LGR6 has been widely reported to serve as an important stem cell marker in multiple cancer types, which significantly contributed to carcinogenesis and progression of cancer. 28, 29 Paradoxically, two literatures have reported that LGR6 potentially functioned as a tumor suppressor in colon cancer and breast cancer. 24, 30 These findings suggest that the pro-and anti-tumor roles of LGR6 are tumor type dependent. In ovarian cancer, LGR6 has been found to be associated with the development and progression of high-grade serous ovarian carcinoma. 31 However, the clinical significance and functional role of LGR6 in ovarian cancer remains not reported yet. In this study, our results reported that LGR6 was differentially upregulated in different histologic types of ovarian cancer, particularly in high-grade serous adenocarcinoma, and high expression of LGR6 positively correlated with histologic types, FIGO stages, poor chemotherapeutic response, and poor progression in ovarian cancer patients. Furthermore, functional experiments showed that silencing LGR6 inhibited CSC properties and attenuated chemoresistance in ovarian cancer cells via inactivating Wnt/b-catenin signaling. Collectively, our results determine the oncogenic role of LGR6 in ovarian cancer.
Similar to the controversial roles of LGR6 in different types of cancer, LGR proteins, including LGR4-6, have been demonstrated to play an opposite, even paradoxical, role in regulating Wnt/b-catenin signaling. Several lines of evidence have reported that LGR4-6 enhances activity of Wnt/b-catenin signaling via binding to R-spondins. [22] [23] [24] However, LGR5 was found to play a negative role in Wnt signaling in colorectal cancer, 32, 33 suggesting that the exact roles of LGR4-6 in Wnt signaling and tumorigenesis appear to vary depending on the given cellular context. Notably, Wnt signaling augmented by LGR6 has been reported to support the development and progression of high-grade serous ovarian carcinoma. 31 Consistently, our findings found that silencing LGR6 robustly inhibited Wnt/b-catenin signaling in ovarian cancer cells. More importantly, repression of Wnt/b-catenin signaling by LGR6 downregulation inhibited CSC characteristics as well as enhanced the sensitivity of ovarian cancer cells to chemotherapeutics. Thus, our results provide a novel finding that LGR6 promotes stemness and chemoresistance via activating Wnt/b-catenin signaling in ovarian cancer. However, the specific mechanism underlying LGR6-induced activation of Wnt/b-catenin signaling in ovarian cancer remains unclear, which requires further investigation in the following work.
The presence of CSCs has been extensively reported to be a major contributor for the chemotherapeutic resistance in ovarian cancer. A study from Janzen et al. 6 has reported that an apoptosis-enhancing drug, birinapant, aimed at eliminating the CSC subpopulation in ovarian cancer, re-sensitized ovarian cancer cells to carboplatin via cleavage of caspase 8 and restoration of apoptosis caused by degradation of baculoviral IAP repeat containing 3 (cIAP). Furthermore, the dual prostaglandin-endoperoxide synthase/lipoxygenase (COX/ LOX) inhibitor licofelone improved the efficacy of paclitaxel in ovarian cancer by suppressing tumor stem-like properties. 7 These studies have indicated that therapeutic strategy targeting CSCs is an effective avenue in improving chemoresistance in ovarian cancer. In this study, our results showed that silencing LGR6 repressed stemness in ovarian cancer cells. Importantly, inhibition of CSC-like phenotypes by LGR6 downregulation dramatically improved the chemoresistance of ovarian cancer cells to cisplatin and paclitaxel. In fact, several studies have demonstrated that LGR6 marks stem cells in www.moleculartherapy.org normal human tissues, including mammary gland, 34 skin, 35 lung, 36 and taste buds, 37 as well as in cancerous tissues, 38 providing the evidence that LGR6 serves as an important marker in maintaining stem cell properties. Therefore, our results in combination with other studies suggest that LGR6 may serve as a novel therapeutic target in the treatment of chemoresistant ovarian cancer.
In summary, our findings demonstrate that LGR6 promotes the chemoresistance of ovarian cancer cells to cisplatin via activating Wnt/ b-catenin signaling pathway. Thus, better identification of the underlying mechanism responsible for the pro-chemoresistance role of LGR6 in ovarian cancer will enhance our understanding for the chemoresistance in ovarian cancer, which will facilitate the development of novel therapeutic target against ovarian cancer.
MATERIALS AND METHODS
Cell Lines and Cell Culture
The ovarian epithelial cell line HOSEpiC was purchased from ProCells, and the ovarian cancer cell lines A2780, OVCAR-3, ES-2, PA-1, SW628, TOV-21G, SK-OV-3, and Caov-3 were obtained from the Shanghai Chinese Academy of Sciences cell bank (China), and all human ovarian cancer cell lines were maintained in RPMI 1640 (Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS) (HyClone, USA). All ovarian cancer cells were cultured at 37 C in a humidified atmosphere with 5% CO 2 .
RNA Extraction, Reverse Transcription, and Real-Time PCR
The RNA from tissues or cells was extracted using TRIzol (Life Technologies) according to the manufacturer's instructions. www.moleculartherapy.org Molecular Therapy: Oncolytics Vol. 14 September 2019mRNAs were polyadenylated using a poly(A) polymerase-based first-strand synthesis kit (TaKaRa, DaLian, China), and reverse transcription (RT) of total mRNA was performed using a PrimeScript RT reagent kit (TaKaRa) according to the manufacturer's protocol. cDNA was amplified and quantified on ABI 7500HT system (Applied Biosystems, Foster City, CA, USA) using SYBR green I (Applied Biosystems). The primers used in the reactions were listed in Table S4 . Real-time PCR was performed as described previously. 39 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as endogenous controls. Relative fold expressions were calculated with the comparative threshold cycle (2 ÀDDCt ) method as previously described. 40 
Western Blotting Analysis
Western blot was performed as described previously. 41 A cell fractionation kit (Cell Signaling Technology, USA) was used for nuclear fractionation. Antibodies against LGR6 and LGR4 were purchased from Proteintech, LGR5 and b-catenin from Invitrogen, and Bcl-2 and Bcl-xL from Cell Signaling Technology. a-tubulin antibody (Cell Signaling Technology) served as the loading control.
Immunohistochemistry
The immunohistochemistry was carried out as previously described. 
CCK-8 Analysis
A total of 2 Â 10 3 cells were seeded into each well of 96 plates. The specific staining process and methods were performed as previously described. 43 
Side-Population Analysis
The cell suspensions were labeled with Hoechst 33342 (Molecular Probes, #H-3570) dye for side-population analysis as per standard protocol. 44 In brief, cells were resuspended at 1Â pre-warmed OptiMEM (Gibco, USA) containing 2% FBS (Gibco, USA) at a density of 10 6 /mL. Hoechst 33342 dye was added at a final concentration of 5 mg/mL in the presence or absence of verapamil (50 mmol/L; Sigma) and the cells were incubated at 37 C for 90 min with intermittent shaking. At the end of the incubation, the cells were washed with OptiMem containing 2% FBS, centrifuged down at 4 C, and resuspended in ice-cold OptiMem containing 2% FBS and 10 mmol/L HEPES. Propidium iodide (PI, Sigma, USA) at a final concentration of 2 lg/mL was added to the cells to gate viable cells. The cells were filtered through a 40 mm cell strainer to obtain single-cell suspension before sorting. Analysis and sorting was done on a FACS AriaI (Becton Dickinson). The Hoechst 33342 dye was excited at 355 nm and its dual-wavelength emission at blue and red regions was plotted to get the SP scatter.
Spheroid Formation Assay
Cells (500 cells/well) were seeded into 6-well ultra low cluster plates (Corning) and cultured as previously described. 45 After 10-12 days, the number of cell spheroids (tight, spherical, non-adherent masses >50 mm in diameter) were counted, and images of the spheroids were scored under an inverse microscope (spheroid formation efficiency = colonies/input cells Â 100%).
Flow Cytometric Analysis
Flow cytometric analysis of apoptosis used the fluorescein isothiocyanate (FITC) Annexin V apoptosis detection kit I (BD Biosciences, USA) and was presented as protocol described. In brief, cells were dissociated with trypsin and resuspended at 1 Â 10 6 cells/mL in binding buffer with 50 mL/mL FITC Annexin V and 50 mL/mL PI. The cells were subsequently incubated for 15 min at room temperature and then were analyzed by Gallios flow cytometer (Beckman Coulter, USA). The cell's inner mitochondrial membrane potential (Dcm) was detected by flow cytometry using MitoScreen JC-1 staining kit (BD Biosciences) and was performed as previously described. 46 Flow cytometry data were analyzed using FlowJo 7.6 software (TreeStar, USA).
Caspase-9 or Caspase-3 Activity Assays Activity of caspase-9 or caspase-3 was analyzed by spectrophotometry using a caspase-9 colorimetric assay kit or caspase-3 colorimetric assay kit (Keygen, China) and was performed as previously described. 25 The absorbance was measured at 405 nm, and bicinchoninic acid (BCA) protein quantitative analysis was used as the reference to normal each experiment groups.
Tumor Xenografts
The 6-week-old BALB/c-nu mice were randomly divided into two groups (n = 5 per group). 1 Â 10 6 SK-OV-3 cells per mouse were inoculated subcutaneously into the inguinal folds of the nude mice. After 12 days of cell inoculation, the mice were injected intraperitoneally with 2 mg/kg cisplatin every 5 days for 3 weeks. Tumor volume was determined using an external caliper and calculated using the equation (L Â W 2 )/2. On day 42, animals were euthanized, and the tumors were excised, weighed, and stored in liquid nitrogen tanks.
Luciferase Assay
Cells (4 Â 10 4 ) were seeded in triplicate in 24-well plates and cultured for 24 h, and the luciferase reporter assay was performed as previously described. 47 Cells were transfected with 100 ng TOP-flash or FOPflash luciferase reporter plasmid, plus 5 ng pRL-TK Renilla plasmid (E2241; Promega) using Lipofectamine 3000 (Invitrogen) according to the manufacturer's recommendation. Luciferase and Renilla signals were measured 36 h after transfection using a dual luciferase reporter assay kit (Promega) according to the manufacturer's protocol.
Agent, Plasmid, and Transfection S33Y and pcDNA3-S33Y b-catenin were purchased from Addgene (#19286). The reporter plasmids containing wild-type (CCTTT GATC; TOPflash, #12456, Addgene) or mutated (CCTTTGGCC; FOPflash, #12457, Addgene) T cell factor/lymphoid enhance factor (TCF/LEF) DNA binding sites were purchased from Upstate Biotechnology. Knockdown of endogenous LGR6 was performed by cloning two short hairpin RNA (shRNA) oligonucleotides into the pSUPERpuro-retro vector (OligoEngine, Seattle, WA, USA). Two separate shRNA fragments of LGR6 are listed in Table S5 . Plasmid transfection was performed according to the protocol of Lipofectamine 3000 (Life Technologies).
Patients and Tumor Tissues
Six fresh ovarian cancer tissues and four normal ovarian epithelial tissues, as well as individual 294 paraffin-embedded, archived ovarian cancer tissues and 40 normal ovarian epithelial tissues were obtained during surgery at from the Clinical Biobank of Collaborative Innovation Center for Medical Molecular Diagnostics of Guangdong Province, the Affiliated Jiangmen Hospital of Sun Yat-sen University (Guangdong, China) between January 2008 and December 2017 (Tables S1, S2 , and S6). Patients were diagnosed based on clinical and pathological evidence, and the specimens were immediately snap-frozen and stored in liquid nitrogen tanks. For the use of these clinical materials for research purposes, prior patients' consents and approval from the Institutional Research Ethics Committee were obtained.
Statistical Analysis
All values are presented as means ± SD. Significant differences were determined using GraphPad 5.0 software (USA). Student's t test was used to determine statistical differences between two groups. One-way ANOVA was used to determine statistical differences between multiple testing. The chi-square test was used to analyze the relationship between LGR6 expression and clinicopathological characteristics. Survival curves were plotted using the Kaplan-Meier method and compared by log-rank test. p < 0.05 was considered significant. All the experiments were repeated three times.
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